Definition of unique and shared T-cell defined tumor antigens in human renal cell carcinoma

Journal of Immunotherapy

Volumn 21, Issue 6, 1998, Pages 427-434

  Brouwenstijn, Nathalie ^a   Hoogstraten, Connie ^a   Verdegaal, Els M E ^a   Van Der Spek, Corry W ^a   Deckers, Joan G ^a   Mulder, Arend ^a,b   Osanto, Susanne ^a   Schrier, Peter I ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SVM Foundation for the Advancement of Public Health and Environmental Protection   (Netherlands)

Author keywords

Cytotoxic T cells; Melanoma; Renal cell carcinoma; Self antigens; Tumor associated antigens

Indexed keywords

HLA A1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; RNA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR VACCINE;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOGENICITY; KIDNEY CARCINOMA; LYMPHOBLASTOID CELL; MELANOMA; MIXED LYMPHOCYTE CULTURE; MONONUCLEAR CELL; PRIORITY JOURNAL; VACCINE PRODUCTION;

EID: 0031726516     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199811000-00004     Document Type: Article

References (36)

1. Cronin RE. Renal cell carcinoma. Am J Med Sci 1991;302:249-59.
2. Heicappell R, Ackermann R. Rationale for immunotherapy of renal cell carcinoma. Urol Res 1990;18:357-72.
3. Belldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 1988;48:206-14.
4. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 1989;63:128-31.
5. Brouwenstijn N, Gaugler B, Kruse KM, et al. Renal cell carcinoma-specific lysis by CTL clones isolated from peripheral blood lymphocytes and tumor infiltrating lymphocytes. Int J Cancer 1996;68:177-82.
6. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-84.
7. Schendel DJ, Gansbacher B, Oberneder R, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993;151:4209-20.
8. Bernhard H, Karbach J, Wolfel T, et al. Cellular immune response to human renal cell carcinomas: Definition of a common antigen recognized by HLA-A2 restricted cytotoxic T lymphocyte (CTL) clones. Int J Cancer 1994;59:837-42.
9. Finke JH, Rayman P, Edinger M, et al. Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 1992;11:1-11.
10. Gaugler B, Brouwenstijn N, Vantomme V, et al. A new gene coding for an antigen recognized by autologous CTL on a human renal carcinoma. Immunogenetics 1996;44:323-30.
11. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996;8:628-36.
12. Kudoh S, Stanley J, Edinger MG, et al. T lymphocytes infiltrating renal cell carcinoma have a reduced expression of transferrin receptor. hit J Cancer 1994;58:369-75.
13. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993;53:5613-6.
14. Detrisac CJ, Sens MA, Garvin AJ, Spicer SS, Sens DA. Tissue culture of human kidney epithelial cells of proximal tubule origin. Kidney Int 1984;25:383-90.
15. van der Woude FJ, Michael AF, Muller E, van der Hem GK, Vernier RL, Kim Y. Lymphohaemopoiedc antigens of cultured human glomerular epithelial cells. Br J Exp Pathol 1989;70:73-82.
16. Muller EW, Kim Y, Michael AF, Vernier RL, van der Hem GK, van der Woude FJ. Explantation of mesangial cell ‘hillocks’: a method for obtaining human mesangial cells in culture. Int J Exp Pathol 1992;73:9-20.
17. Versteeg R, Noordermeer IA, Kriise-Wolters KM, Ruiter DJ, Schrier PI. c-Myc downregulates class I HLA expression in human melanomas. EMBO J 1988;7:1023-9.
18. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986;95:99-105.
19. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
20. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986;38:489-94.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
22. Guilloux Y, Lucas S, Brichard VG, et al. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 1996;183:1173-83.
23. Brasseur F, Marchand M, Vanwijck R, et al. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer 1992;52:839-41.
24. De Smet C, Lurquin C, van der Bruggen P, De Plaen E, Brasseur F, Boon T. Sequence and expression pattern of the human MAGE2 gene. Immunogenetics 1994;39:121-9.
25. De Plaen E, Arden K, Traversari C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994;40:360-9.
26. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-75.
27. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-98.
28. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338:1227-9.
29. Adema GJ, De Boer AJ, Vogel AM, Loenen WAM, Figdor CG. Molecular characterization of the melanocyte lineage-specific antigen gplOO. J Biol Chem 1994;269:20126-33.
30. Brouwenstijn N, Slager EH, Bakker ABH, et al. Transcription of the gene encoding melanoma-associated antigen gplOO in tissues and cell lines other than those of the melanocytic lineage. Br J Cancer 1997;76:1562-6.
31. Robbins PF, el-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-92.
32. Wolfel T, Hauer M, Schneider J, et al. A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
33. Coulie PG, Lehmann F, Lethe B, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995;92: 7976-80.
34. Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
35. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol 1996;8:75-81.
36. Moretta A, Bottino C, Pende D, et al. Identification of four subsets of human CD3- CD 16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990;172:1589-98.